• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
FDMT

FDMT

4D Molecular Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD9.53

+0.26 (+2.80%)

Rating:C+

Company Profile

CEO

David H. Kirn

IPO Date

2020-12-11

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$9.28

Prev. Close

$9.27

Day Low

$8.97

Day High

$9.65

52W Low

$3.68

52W High

$12.34

Market Cap

$0.50B

Volume

0.91M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

7

Avg Positive

34.6%

Avg Negative

1.3%

Avg Neutral

64.1%

News Feed

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement

GlobeNewsWire·6/24/2021·↑ positive

4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

GlobeNewsWire·5/13/2021·↑ positive

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

GlobeNewsWire·5/12/2021·↑ positive

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

GlobeNewsWire·4/30/2021·↑ positive

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

GlobeNewsWire·4/27/2021·↑ positive

4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights

GlobeNewsWire·3/25/2021·↑ positive

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease

GlobeNewsWire·3/9/2021·↑ positive